Table 3.
SC source | Dose and Route of administration | No. | Phase | Status | Location | Study design | Identifier |
---|---|---|---|---|---|---|---|
BM-MSCs | |||||||
BM-MSCs | A single dose of 1–2 × 10 6 cells/kg, IV | 9 | 1 | Recruiting | Sweden | Interventional, Single Group Assignment, Open-Label Masking | NCT04447833 |
BM-MSCs | Three times of 1.5–3 × 106 cells/kg, IV | 20 | 1|2 | Recruiting | Belgium | Single Group Assignment, Open Label | NCT04445454 |
BM-MSCs | Two doses of 2 × 106 cells/kg, IV | 20 | 2 | Recruiting | Pakistan | Randomized, Parallel Assignment, Open Label | NCT04444271 |
BM-MSCs | Gp 1: Three doses of 25 × 10 6 cells/kg, IV Gp 2: Three doses of 50 × 10 6 cells/kg, IV Gp 3: Three doses of 90 × 10 6 cells/kg, IV |
9 | 1 | Recruiting | Canada | Non-Randomize, Interventional, Sequential Assignment, Open Label | NCT04400032 |
BM-MSCs | NA | 45 | 1 | Recruiting | USA | Randomized, Parallel Assignment, Quadruple Masking | NCT04397796 |
BM-MSCs | NA | 10 | NA | Not yet recruiting | UK | Observational, Case-Only, Prospective | NCT04397471 |
BM-MSCs | NA | 40 | 2 | Not yet recruiting | Germany | Randomized, Parallel Assignment, Open Label | NCT04377334 |
BM-MSCs | Two doses of 2 × 106 cells/kg, IV | 223 | 3 | Active, not recruiting | USA | Randomized, Parallel Assignment, Triple Masking | NCT04371393 |
BM-MSCs | A single dose of 1 × 106 cells/kg, IV | 20 | 1|2 | Not yet recruiting | China | Randomized, Parallel Assignment, Single Masking | NCT04346368 |
BM-MSCs | Four doses of 1 × 108 cells/kg, IV | 30 | 1 | Not yet recruiting | USA | Single group, Parallel Assignment, Open Label | NCT04345601 |
BM-MSCs | A single dose of 1 × 106 cells/kg | 10 | 1 | Not yet recruiting | Brazil | Single Group Assignment-Open Label | NCT04467047 |
BM-MSCs | A single dose of 2 × 106 cells/kg | 600 | NA | Completed | Pakistan | Non-Randomized, Factorial Assignment, Open Label | NCT04492501 |
BM-MSCs | Two doses, IV | 40 | 2 | Recruiting | USA | Randomized, Parallel Assignment, Quadruple Masking, double-blind | NCT04780685 |
UC-MSCs | |||||||
UC-MSCs | A single dose, IV | 40 | 1 | Completed | USA | Randomized, Single Group Assignment, Triple Masking | NCT04573270 |
UC-MSCs | Two doses of 10 × 107 cells, IV | 60 | 1|2 | Recruiting | USA | Randomized, Parallel Assignment, Triple Masking | NCT04494386 |
UC-MSCs | Two doses of 10 × 107 cells, IV | 21 | 1|2 | Not yet recruiting | USA | Randomized, Parallel Assignment, Double Masking | NCT04490486 |
UC-MSCs | A single dose of 1 × 106 cells/kg, IV | 40 | 1 | Recruiting | Indonesia | Randomized, Interventional, Parallel Assignment, Triple Masking | NCT04457609 |
UC-MSCs | Single-dose of 0.5, 1, 1.5 × 106 cells/kg, IV | 39 | 1|2 | Not yet recruiting | USA | Non-Randomized, Sequential Assignment, Open Label | NCT04452097 |
UC-MSCs | 5 × 105 cells/kg, IV | 20 | 2 | Recruiting | Pakistan | Randomized, Parallel Assignment, Open Label | NCT04437823 |
UC-MSCs | A single dose of 1 × 106 cells/kg, IV | 30 | 2 | Not yet recruiting | Colombia | Randomized, Parallel Assignment, Triple Masking | NCT04429763 |
UC-MSCs | 1 × 106 cells/kg, IV | 10 | 2 | Recruiting | Mexico | Allocation: Non-Randomized, Parallel Assignment, Open Label | NCT04416139 |
UC-MSCs | Three doses of 1 × 106 cells/kg | 30 | 1|2 | Recruiting | USA | Randomized, Single Group Assignment, Quadruple Masking | NCT04399889 |
UC-MSCs | A single dose of 1 × 106 cells/kg | 70 | 1|2 | Not yet recruiting | USA | Randomized, Parallel Assignment, Double Masking | NCT04398303 |
UC-MSCs | Three doses 3 × 10 6 cells, IV | 30 | 1|2 | Recruiting | Turkey | Randomized, Parallel Assignment, Quadruple Masking | NCT04392778 |
UC-MSCs | Two doses of 50 × 106 cells, IV | 40 | 1|2 | Not yet recruiting | Colombia | Randomized, Parallel Assignment, Quadruple Masking | NCT04390152 |
UC-MSCs | Four doses of 1 × 106 cells, IV | 60 | 1 | Active, not recruiting | China | Randomized, Parallel Assignment, Open Label | NCT04371601 |
UC-MSCs | NA | 106 | 2 | Recruiting | Spain | Randomized, Parallel Assignment, open-label | NCT04366271 |
UC-MSCs | Two doses of 100 × 106 cells, IV | 24 | 1|2 | Completed | USA | Randomized, Parallel Assignment, Triple Masking | NCT04355728 |
UC-MSCs | Three doses of 4 × 107 cells, IV | 100 | 2 | Completed | China | Randomized, Parallel Assignment, Quadruple Masking | NCT04288102 |
UC-MSCs | Four doses of 5 × 106 cells, IV | 48 | NA | Not yet recruiting | China | Randomized, Parallel Assignment, Open Label | NCT04273646 |
UC-MSCs | Four doses of 9.9 × 107 cells, IV | 16 | 2 | Recruiting | China | Non-randomized, Single Group Assignment, Open Label | NCT04269525 |
UC-MSCs | Three doses of 3 × 107 cells, IV | 20 | 1 | Recruiting | China | Non-Randomized, Parallel Assignment, Open Label | NCT04252118 |
UC-MSCs | Two doses of 1 × 106 cells/kg, IV | 30 | 1|2 | Recruiting | China | Randomized, Parallel Assignment, Triple Masking | NCT04339660 |
UC-MSCs | A single dose of 4 × 108 cells, IV | 75 | 1|2 | Recruiting | UK | Randomized, Parallel Assignment, Quadruple Masking | NCT03042143 |
UCWJ-MSCs | Three doses of 1 × 106 cells, IV | 47 | 1|2 | Active, not recruiting | France | Randomized, Interventional, Parallel Assignment, Triple Masking | NCT04333368 |
CB-MSCs | NA, IV | 70 | 1 | Recruiting | USA | Randomized, Parallel Assignment, Open Label | NCT04565665 |
PLX-PAD | High and low doses, IV | 140 | 2 | Recruiting | USA | Randomized, Parallel Assignment, Quadruple Masking | NCT04389450 |
PLX-PAD | A single dose of 3 × 108 cells, IV | 40 | 2 | Recruiting | Israel | Randomized, Parallel Assignment, Open Label | NCT04614025 |
Placenta-MSCs | Three doses of 1 × 106 cells/kg, IV | 30 | 1|2 | Recruiting | Ukraine | Non-Randomized, Parallel Assignment, Open Label | NCT04461925 |
Embryonic SCs | 1 × 106 cells | 9 | 1|2 | Recruiting | China | Interventional, Open Label | NCT04331613 |
WJ-MSCs | |||||||
WJ-MSCs | Three doses of 106 cells/kg | 30 | 2 | Not yet recruiting | Spain | Randomized, Single Group Assignment, Quadruple Masking | NCT04625738 |
WJ-MSCs | A single dose of 10 × 107 cells, IV | 9 | 1 | Active, not recruiting | Mexico | Single Group Assignment, Open Label | NCT04456361 |
WJ-MSCs | 106 cells, IV | 30 | 1|2 | Recruiting | Spain | Randomized, Parallel Assignment, Quadruple Masking | NCT04390139 |
WJ-MSCs | Four doses of 1 × 106 cells/kg, IV | 5 | 1 | Recruiting | Jordan | Single Group Assignment, Open Label | NCT04313322 |
AD-MSCs | |||||||
AD-MSCs | A single dose of 1 × 106 cells/kg, IV | 20 | 1 | Recruiting | Mexico | Randomized, Parallel Assignment, Open Label | NCT04611256 |
AD-MSCs | NA | 10 | 1|2 | Not yet recruiting | Korea | Single Group Assignment, Open Label | NCT04527224 |
AD-MSCs | four times 10 × 107 cells/time | 6 | 1 | Not yet recruiting | Japan | Single Group Assignment, Open Label | NCT04522986 |
AD-MSCs | NA, IV | 20 | 1 | Recruiting | USA | Interventional, Single Group Assignment, Open Label | NCT04486001 |
AD-MSCs | Five doses of 1 × 108 cells | 20 | 2 | Recruiting | USA | Interventional, Single Group Assignment, Open Label | NCT04349631 |
AD-MSCs | Three doses of 20 × 107 cells, IV | 200 | 2 | Not yet recruiting | USA | Randomized, Parallel Assignment, Double Masking | NCT04428801 |
AD-MSCs | Five doses of 2 × 108, 1 × 108, 5 × 107 cells, IV | 100 | 2 | Enrolling by invitation | USA | Randomized, Parallel Assignment, Quadruple Masking | NCT04348435 |
AD-MSCs | Two doses of 8 × 10 7 cells, IV | 26 | 1|2 | Active, not recruiting | Spain | Randomized, Parallel Assignment, Open Label | NCT04366323 |
AD-MSCs | 5 × 10 7 cells/kg, IV | 20 | 1 | Not yet recruiting | USA | Non-Randomized, Sequential Assignment, Open Label | NCT04352803 |
AD-MSCs | Four doses of 1 × 108 cells, IV | 100 | 2 | Active, not recruiting | USA | Randomized, Parallel Assignment, Quadruple Masking | NCT04362189 |
AD-MSCs | Two doses of 1.5 × 106 cells/kg | 100 | 2 | Not yet recruiting | Spain | Randomized, Parallel Assignment-Quadruple Masking-Multi center | NCT04348461 |
AD-MSCs | 1–1.5 × 106 cells/kg | 100 | 2 | Not yet recruiting | USA | Randomized, Parallel Assignment, Double Masking | NCT04728698 |
AD-MSCs | Five doses, IV | 56 | 2 | Active, not recruiting | USA | Interventional, Single Group Assignment, Open Label | NCT04349631 |
Other Sources | |||||||
DP-MSCs | Three doses of 3 × 107, IV | 20 | 1|2 | Recruiting | China | Randomized, Interventional. Parallel Assignment, Triple Masking | NCT04336254 |
DP-MSCs | Three doses of 1 × 106 cells, IV | 24 | 1 | Not yet recruiting | China | Interventional, Single Group Assignment, Open Label | NCT04302519 |
LMSCs | Three doses of 1 × 108 cells, IV | 70 | 1 | Recruiting | USA | Randomized, Parallel Assignment, Double Masking | NCT04629105 |
Cymerus MSCs | 2 million cells/kg, IV | 24 | 1|2 | Recruiting | Australia | Randomized, Parallel Assignment, Open Label | NCT04537351 |
RNA-engineered | NA | 30 | 1|2 | Recruiting | USA | Single Group Assignment, Open Label | NCT04524962 |
Olfactory MSCs | NA, IV | 40 | 1|2 | Enrolling by invitation | Belarus | Non-Randomized, Parallel Assignment, Open Label | NCT04382547 |
SCE | A single dose, IV | 20 | 2 | Not yet recruiting | China | Randomized, Parallel Assignment, Single Masking | NCT04299152 |
NHPBSCs | 1 × 106 cells, IV | 146 | 1|2 | Completed | UAE | Randomized, Open-Label | NCT04473170 |
Progenitor | NA, IV | 400 | 2|3 | Recruiting | USA | Randomized, Parallel Assignment, Quadruple Masking, | NCT04367077 |
Undefined-MSCs | |||||||
MSCs | Three doses of 300 × 10, IV | 30 | 2 | Recruiting | USA | Randomized, placebo-controlled-parallel assignment, Triple Masking | NCT04466098 |
MSCs | 250 to 750 million | 22 | 1|2 | Recruiting | USA | Randomized, Interventional, Parallel Assignment, Quadruple Masking | NCT04445220 |
MSCs | A single dose of 1 × 10 6 cells/kg | 20 | 2 | Recruiting | Spain | Randomized, Parallel Assignment, Double Masking | NCT04615429 |
MSCs | A single dose of 2.5,5 or 10 × 107 cells, IV | 20 | 1 | Recruiting | Brazil | Randomized, Parallel Assignment, Open Label | NCT04525378 |
MSCs | Four doses of 2 × 10 7 cells, IV | 90 | 2 | Not yet recruiting | Brazil | Interventional, Parallel Assignment, Quadruple Masking | NCT04315987 |
MSCs | Three doses of 1 × 10 6 cells/kg | 21 | NA | Completed | Turkey | Randomized, Parallel Assignment, Open Label | NCT04713878 |
MSCs | A single dose of 1 × 10 6 cells/kg, IV | 24 | 2 | Recruiting | Spain | Randomized, Parallel Assignment, Triple Masking | NCT04361942 |
DW-MSCs | Low dose gp: 5 × 107cells, IV High dose gp: 1 × 108 cells, IV |
9 | 1 | Recruiting | Indonesia | Randomized, Interventional, Parallel Assignment, Quadruple Masking | NCT04535856 |
MSC: Mesenchymal stem cell; BM-MSC: Bone marrow-MSC; UC-MSC: Umbilical cord-MSC; CM: Conditioned media; AD-MSCs: Adipocyte derived MSCs; WJ-MSCs: Warton jelly-MSC; CB-MSC: Cord blood-MSC; IMRC: immunity- and matrix-regulatory cell; DP-MSCs: Dental pulp MSCs; LMSCs: Longeveron MSCs; SCE: Stem cell educator; NHPBSC: Non-hematopoietic peripheral blood stem cells; gp: Group; IV: Intravenous; NA: Not available.